Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 6.18B 5.41B 4.97B 4.63B 8.77B 590B 8.93B 59.81B 23.16B 287B 23.2B 22.7B 996B P/E 2026 *
73.8x
P/E 2027 * 39x
Enterprise Value 6.18B 5.41B 4.97B 4.63B 8.77B 590B 8.93B 59.81B 23.16B 287B 23.2B 22.7B 996B EV / Sales 2026 *
21.5x
EV / Sales 2027 * 16.7x
Free-Float
97.62%
Yield 2026 *
-
Yield 2027 * -
1 day+2.42%
1 week+12.16%
Current month+1.09%
1 month+39.07%
3 months+60.08%
6 months+69.01%
Current year+69.01%
1 week 286
Extreme 286
320.99
1 month 231.31
Extreme 231.31
320.99
Current year 175.89
Extreme 175.89
320.99
1 year 112.41
Extreme 112.41
320.99
3 years 49.24
Extreme 49.24
320.99
5 years 49.24
Extreme 49.24
320.99
10 years 49.24
Extreme 49.24
320.99
Manager TitleAgeSince
Chief Executive Officer 66 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 58 27/09/2006
Director/Board Member 66 01/03/2007
Date Insider Type Main position Quantity % Market Cap.
06-16Fiscal year

Director

6,435 0.0321%
06-12Fiscal year

Director

14,461 0.0722%
06-11Sell

Director

-4,500 0.0225%
Change 5-day change 1-year change 3-year change Capi.($)
+2.42%+12.16%+183.89%+343.20% 6.18B
+1.86%+8.65%+56.45%+158.84% 1,063B
+3.57%+9.15%+68.70%+58.92% 611B
+3.99%+11.15%+37.41%+93.77% 444B
-1.20%-0.96%+26.12%+20.22% 324B
+4.94%+4.51%+39.76%+28.93% 285B
+2.42%+2.96%+30.77%+42.24% 283B
+2.47%+6.56%-24.26%-39.60% 219B
+3.55%+6.47%+28.79%+68.52% 195B
+4.21%+4.88%+17.49%+70.33% 156B
Average +1.38%+3.49%+46.51%+84.54% 358.69B
Weighted average by Cap. +0.64%+4.17%+42.18%+81.13%

Financials

2026 *2027 *
Net sales 288M 252M 231M 215M 408M 27.44B 416M 2.78B 1.08B 13.37B 1.08B 1.06B 46.36B 371M 324M 298M 278M 525M 35.34B 536M 3.59B 1.39B 17.22B 1.39B 1.36B 59.72B
Net income 92.7M 81.1M 74.5M 69.44M 131M 8.84B 134M 897M 347M 4.31B 348M 340M 14.94B 178M 156M 143M 133M 253M 17B 258M 1.72B 668M 8.28B 669M 654M 28.71B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Employees
47
Date Price Change Volume
02/07/26 $319.51 +2.40% 368,155
01/07/26 $312.01 -1.29% 521,622
30/06/26 $316.09 +0.65% 879,068
29/06/26 $314.04 +3.44% 539,305
26/06/26 $303.59 +2.59% 1,250,980
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
312.01USD
Average target price
277.60USD
Spread / Average Target
-11.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock